Results 101 to 110 of about 7,521 (213)
Hepatitis B Virus: Inactive carriers [PDF]
, 2005 Inactive carriers forms the largest group in chronic HBV infected patients. Around 300 million people are inactive carriers The inactive HBsAg carrier state is diagnosed by absence of HBeAg and presence of anti-HBe, undetectable or low levels of HBV DNA ...
Saini Nitin +2 more
core +1 more source
HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B [PDF]
Hepatology International, 2009 During the natural history of chronic hepatitis B virus (HBV) infection, the loss of serum hepatitis B e antigen (HBeAg) and the development of anti-HBe antibodies (HBeAg seroconversion) mark a transition from the immune-active phase of disease to the inactive carrier state.
openaire +2 more sources
Insights into the Natural and Treatment Courses of Hepatitis B in Children: A Retrospective Study
BiomedicinesChronic Hepatitis B virus (HBV) infection in children remains a significant public health challenge. The natural history and treatment outcomes of HBV can vary widely, influencing management strategies. This retrospective study was conducted in Northeast
Lorenza Forna +9 more
doaj +1 more source
Then and now: the progress in hepatitis B treatment over the past 20 years. [PDF]
, 2014 The ultimate goals of treating chronic hepatitis B (CHB) is prevention of hepatocellular carcinoma (HCC) and hepatic decompensation. Since the advent of effective antiviral drugs that appeared during the past two decades, considerable advances have been ...
Halegoua-De Marzio, Dina, Hann, Hie-Won
core +2 more sources
Levels of HBV DNA and not HBsAg are associated with biochemical flares after HBeAg seroconversion [PDF]
, 2012 BACKGROUND: The role of HBsAg levels in predicting subsequent flares in chronic hepatitis B patients after HBeAg seroconversion is not known METHODS: Serum HBsAg and HBV DNA levels were determined in 224 CHB patients at 6-12 months after spontaneous ...
Fung, J +4 more
core +1 more source
Chinese Medical Journal, 2018 Background: Until now, various types of combined therapy with nucleotide analogs and pegylated interferon (Peg-INF) in patients with hepatitis B patients have been tried.
Dae Won Jun +21 more
doaj +1 more source
Future prevention and treatment of chronic hepatitis B infection [PDF]
, 2012 Vaccination for hepatitis B virus (HBV) infection and treatment for chronic hepatitis B, while effective for primary prevention and control of the disease, still have their limitations. Global coverage of HBV immunization needs improvement.
Fung, J, Lai, CL, Seto, WK, Yuen, MF
core +1 more source
Serum levels of preS antigen (HBpreSAg) in chronic hepatitis B virus infected patients
Virology Journal, 2007 Background Hepatitis B virus (HBV) infection is a serious health problem worldwide. Treatment recommendation and response are mainly indicated by viral load, e antigen (HBeAg) seroconversion, and ALT levels.
Gu Xiaocheng +8 more
doaj +1 more source
Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus [PDF]
, 2002 Chinese patients with chronic hepatitis B virus (332 with and 44 without cirrhosis-related complications) were studied. Fifty percent of patients
Chan, AOO +8 more
core +1 more source
Infection International, 2014 Abstract Objective To investigate the efficiency of pegylated interferon α therapy for patients with HBeAg-positive chronic hepatitis B (CHB) and explore whether liver histopathological features and other factors might influence HBeAg seroconversion.
Yao-ren Hu +4 more
openaire +1 more source